ࡱ; ZW  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVY[Root Entry  \pCalc Ba=* =@ 8X@"1Calibri1Arial1Arial1Arial1Calibri1Calibri General #,##03._(\$* #,##0_);_(\$* \(#,##0\);_(\$* \-_);_(@_)\(#,##0_);[RED]\(#,##0\)!"($"#,##0_);[RED]"($"#,##0\)'""($"#,##0.00_);[RED]"($"#,##0.00\);6_(\$* #,##0.00_);_(\$* \(#,##0.00\);_(\$* \-??_);_(@_) #,##0.00                + ) , *   (      (  $   (8  $  $ (  $   (  (   `e-table of contents"3condensed consolidated bal"-?consolidated income statem"Hcondensed consolidated sta$3Qcondensed consolidated sta-1Xconsolidated cash flows"cnotes to condensed consolignet loss per shareknote 3 accrued expenses"_onote 5 sharebased compensa$qsnote 5 sharebased compensa-1"Ewnote 6 related party trans$?{note 8 common stock warrants"Inote 10 commitments and co" comparison of the threemon cash flows?item 6 exhibits seqll inc seqll inc-1 seqll inc-2g seqll inc-3TT     3  @@   TABLE OF CONTENTSPAGEPART IFINANCIAL INFORMATIONItem 1. Financial Statements (Unaudited)QCondensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022mCondensed Consolidated Statements of Comprehensive Income for the three months ended March 31, 2025 and 2022.xCondensed Consolidated Statements of Changes in Stockholders Equity for the three months ended March 31, 2023 and 2022.cCondensed Consolidated Statements of Cash Flows for the three months ended March 31, 2025 and 2022.>Notes to Unaudited Condensed Consolidated Financial StatementsItem 2.UManagement s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.:Quantitative and Qualitative Disclosures about Market RiskItem 4.Controls and ProceduresPART IIOTHER INFORMATIONLegal ProceedingsItem 1A. Risk Factors;Unregistered Sales of Equity Securities and Use of ProceedsDefault Upon Senior SecuritiesMine Safety DisclosuresItem 5.Other InformationItem 6.Exhibits Signatures%Condensed Consolidated Balance Sheets March 31, December31,20232022 (Unaudited)AssetsCurrent assetsCash and cash equivalentsMarketable securitiesAccounts receivable, net of allowance for doubtful accounts of $24,507 and $6,016 as of March 31, 2025 and December 31, 2022, respectivelyOther receivables- InventoryPrepaid expensesTotal current assets Other assetsProperty and equipment, net"Operating lease right-of-use asset Total assets$Liabilities and Stockholders EquityCurrent liabilitiesAccounts payableAccrued expenses,Current portion of operating lease liabilityTotal current liabilitiesNon-current liabilities/Operating lease liability, less current portion,Non-convertible promissory notes - long-termTotal non-current liabilitiesTotal liabilities'Commitments and contingencies (Note 10)Stockholders equitybPreferred stock, $0.00001 par value; 20,000,000 shares authorized; 0 shares issued and outstandingCommon stock, $0.00001 par value; 80,000,000 shares authorized; 13,886,379 and 11,886,379 shares issued and outstanding as of March 31, 2025 and December 31, 2022, respectivelyAdditional paid-in capitalAccumulated deficit&Accumulated other comprehensive incomeTotal stockholders equity*Total liabilities and stockholders equityConsolidated Income StatementThree months ended March 31,RevenueSales$- Grant revenue Total revenue Cost of sales Gross profitOperating expensesResearch and developmentGeneral and administrativeTotal operating expensesOperating lossOther (income) and expensesInvestment income/Unrealized gain on equity marketable securities-Realized loss on equity marketable securities Other incomeInterest expenseNet lossOther comprehensive income-Unrealized gain on marketable debt securitiesDLess: reclassification adjustment for net gains included in net loss Net changeTotal comprehensive loss&Net loss per share - basic and diluted2Weighted average common shares - basic and dilutedCCondensed Consolidated Statements of Changes in Stockholders EquityPreferred StockCommon StockAdditional Paid-In#Accumulated Other Comprehensive AccumulatedTotal Stockholders SharesAmountCapitalIncome (Loss)DeficitEquity#Balance as of December 31, 2022 Stock-based compensation expense;Issuance of common stock, net of issuance costs of $300,750Other comprehensive loss Balance as of March 31, 2023Preferred Stock Common StockAccumulated Other Comprehensive Income (Loss)Balance as of December 31, 2021Balance as of March 31, 2022Consolidated Cash Flows$Cash Flows from Operating ActivitiesJAdjustment to reconcile net loss to net cash used in operating activities: DepreciationWrite-off of obsolete inventory6Unrealized (gain)/loss on marketable equity securities=Realized (gain)/loss on marketable debt and equity securitiesProvision for bad debtsStock-based compensationNon-cash lease expense,Changes in operating assets and liabilities:Accounts receivable, net%Net cash used in operating activities$Cash Flows from Investing ActivitiesPurchases of lab equipment)Purchases of marketable equity securities%Sales of marketable equity securities&Maturity of marketable debt securities)Net cash provided by investing activities$Cash Flows from Financing Activities+Proceeds from issuance of common stock, net)Net cash provided by financing activities)Net increase in cash and cash equivalents.Cash and cash equivalents, beginning of period(Cash and cash equivalents, end of periodTSupplemental disclosure of cash flow information and non-cash financing transactions3Right-of-use asset acquired through operating lease4Notes to Condensed Consolidated Financial Statements Raw materialsWork in processTotal inventoryNet Loss per ShareRestricted stock units Stock optionsWarrants for common stockNote 3 Accrued Expenses March31,Accrued interestAccrued bonusesOther Note 5 Share-based CompensationNumber of Options6Weighted- Average Exercise Price per ShareEWeighted Average Remaining Contractual Term (in Years)#Outstanding as of December31, 2022GrantedOutstanding of March31, 2023Exercisable at March31, 2023Number of Shares5Weighted- Average Exercise Priceper Share6Weighted Average Remaining Contractual Term (inYears)"Note 6 Related Party TransactionsMarch 31, 2023December31, 2022Genomic Diagnostic TechnologiesSt. Laurent InstituteSt. Laurent Realty, Inc.Total related party payablesNote 8 Common Stock Warrants Issuance DateRNumber of Shares Issuable Upon Exercise of Outstanding WarrantsExercise PriceExpiration Date 8/30/2018 8/29/2023 9/30/2018 9/29/2023 10/17/2018 10/16/2023 11/2/2018 11/1/2023 11/9/2018 11/8/2023 11/16/2018 11/15/2023 11/29/2018 11/28/2023 12/21/2018 12/20/2023 12/27/2018 12/26/2023 1/31/2019 1/30/20242/7/20192/6/2024 2/21/2019 2/20/2024 3/20/2019 3/18/20244/8/20194/6/2024 11/19/2020 6/30/20241/8/2021 1/11/2021 2/13/2021 3/16/2021 8/31/2021 8/31/2026 8/26/2026 9/29/2021&Note 10 Commitments and Contingencies2023 (remaining) Thereafter$Total undiscounted lease liabilitiesLess effects of discountingTotal lease liabilitiesReported as of March31, 2023:CComparison of the Three-Month Periods Ended March 31, 2025 and 2022 Three months ended March 31,(Unrealized gain on marketable securities&Realized loss on marketable securities&Net loss per share  basic and diluted2Weighted average common shares  basic and diluted Cash FlowsThree Months Ended March 31,$Cash proceeds provided by (used in):Operating activitiesInvesting activitiesFinancing activitiesItem 6. ExhibitsExhibit Number DescriptionCertification of the Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.Certification of the Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.Certifications of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.Certifications of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the <Sarbanes-Oxley Act of 2002.101.INSInline XBRL Instance Document.101.SCH/Inline XBRL Taxonomy Extension Schema Document.101.CAL=Inline XBRL Taxonomy Extension Calculation Linkbase Document.101.DEF<Inline XBRL Taxonomy Extension Definition Linkbase Document.101.LAB7Inline XBRL Taxonomy Extension Label Linkbase Document.101.PRE>Inline XBRL Taxonomy Extension Presentation Linkbase Document.YCover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). Seqll INCDate: May 9, 2023By:/s/ Daniel JonesName: Daniel JonesTitle:Chief Executive Officer/s/ Frances ScallyFrances ScallyChief Financial Officer` `cc   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} }  } ,,,,,,, , , , , ,,,,,,,,,,    ~   ~  ~  ~  ~   ~   ~    ~ :  ~ N  ~ N  ~ R  ~ R  ~ R  ~ R  ~ R  ~ R  ~ R  ~ V ~ V PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} d} }  } }  } - ,,, , ,,, , , , , ,,,,,,,,,,,,,,,,,     ! "  # $ % &~ .3~  '~ z]~ V (~ *~ zK ) *~  + *~ r ,~ a~ N} -~ ~ " . /~ ZI"~ Z 0~ B~ D .~ ~ B 1~ ~  2 3 4~ 6~ % 5~ _~ = 6~ d~  7~ nY~ J 8 9~ 9U~ 'X :~ bS~ bS ;~ F&~ >!,#,%,&,',(,),*,+,,, !<~ !~ ! #= %> &? &* &* '@~ '.~ ' (A~ ("b~ ("r )B~ )Zp-~ )Q *C~ *N~ *^ +D~ +~ +  ,E~ ,,~ ,,,,,,PH 0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} D} }  } }  } ', @,,,,, , ,,,,,,,,,,,,,,,, F G ! " H   I J J K *~  L *~  M * * N *~  O P~ Bh/~ :m Q~ ;~ # R~ Jk~ 8 S~ ~  T U~ ֐ * V *~ R W *~ R} X *~ b Y~ ~  Z~ ~ z [ \~  * ]~  * ,",$,&, ^~  * "_~ " ؖ"~ "z" $`~ $$~ $$ &a~ &~ &|b """"$$$$PH0 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} ;} } } } }  } } }  } }  } }  } }  } }  }  , @ @ @ , , , , @ b c  d  e f g h i j  i  j k l m n o * J~  |~ ~ "r~ ^~ Q~   p * *  * *~   * *~   q * *~  z~ R~ z[ * *~ ʁ[ r * *  * * *~ ~  Z * * * * * *~ ~  s * J ~ O~ . ~ "b ~ N ~ Zp- ~          PH@0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } } } }  } } } } }  } } } }  } }  }   , , , , , , t  u  e v g h i j  i  j k w m n x * J~  |~ ~ (c J~ ?~ i p * *  * *~ i * *~ i Z * *  * * * *~ z~ z y * J~  |~ ~ f J~ W~   PHP0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} T} }  } }  } ,, @,,,,, , , , , ,,,,,,,,,,,,,,,,, z G ! " {   Z~ ~ z | }~ ~ " ~~ r *  *~ R ~ ~ R} ~ n * ~  ~ i ~ ~ ֭   *~  ) *~ n< ,~ >~ j + *~  .~ z~ J 4~ ~  5~ "~ 6 ~ 2~   ~ 9~   *~   *~ jg ~  * ~ ~ ֎f ,!,",$,&,(,*,+,  !~ !ʁ[ !* "~ "ʁ[ "* $~ $zî~ $v' &~ &~ &b (~ (.3(~ (ֺ( * + +J+~ +nZ+b ((((++++PH`0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } } }  }  ,,,,,,,     ! "    J~   *~ v'  J~ r Z PHp0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  } ,,,,,,   ! " ~ ! * ~ d~ >Oz ~ f ~ & "PH 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  ,,,,,,, ,     ! "   ~ ~  ~ 9~ b= ~ ze~ &F~ _ ~ = Z   PH$0(  $>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} #} }  }  } }  , @ , , , ,       ~ >Oz~ ~   ~ !~ ~  * ~ d~ ~  ~ Z=L~ ~  B PH(0(  (>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} #} }  }  } }   @ , , , ,       * J  * ~ !~ ~  * ~ !~ ~    * J  *: PH,0(  ,>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  , @,,,,,       J~ v ~ ~ / ~ v~ v ~ ~ J PH00(  0>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  }  } }  , @ , , , , , , , , , , , , , , , , , , , , , , , , ,,       ~ B0~    ~ j~    ~ Z~ c   ~ ~    ~ ~    ~ ~    ~ ~    ~ ~    ~ ~    ~ ~    ~ *~    ~ ~    ~ ~    ~ 4~    ~ *~    ~ VAffffff@   ~ Vffffff@   ~ Vffffff@   ~ ffffff@   ~ Vffffff@   ~ ffffff@   ~ Vffffff@   ~ b~    ~ V 33333@   ~ 33333@  ~ f      PH40(  4>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} /} }  } ,,,,,,, , , , ,,,,  ~ k ~ ~ ~ ~ W~ ~ ~ ~ Bf ~ {! ~ Yq  ~ D ~ ]   6~ d 9~ 9U ~ ]2  PH80(  8>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} D} }  } }  } ', @,,,,, , ,,,,,,,,,,,,,,,,   ! " H   I J J K *~  L *~  M * * N *~  O P~ Bh/~ :m Q~ ;~ # R~ Jk~ 8 S~ ~  T U~ ֐ *  *~ R  *~ R} X *~ b Y~ ~  Z~ ~ z [ \~  * ]~  * ,",$,&, ^~  * "_~ " ؖ"~ "z" $~ $$~ $$ &~ &~ &|b """"$$$$PH<0(  <>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} )} }  } }  }  , @,,,,, ,   ! "    ~ 2~  ~ ~ ֎f ~ ʁ[ * ~ zî ~ v' R   PH@0(  @>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} , @,,, , ,,,,,,,  ! ~  0 ~  0 ~  +2  @@             ~   PHD0(  D>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } } ,,,,,,       " "       "PH H0(  H>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } } ,,,,,,       ""      "PH0L0(  L>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } ,,,,,    #           PH@P0(  P>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } ,,,,,    #         PHPT0(  T>@<dgg   FMicrosoft Excel 97-TabelleBiff8Oh+'0|8 @ L X d p0@@@/@/՜.+,D՜.+,\ H AppVersion DocSecurityHyperlinksChangedLinksUpToDate ScaleCrop ShareDoc12.0000 Root EntryFXWorkbookCompObjIOle SummaryInformation(DocumentSummaryInformation8h